| Symbol | REVBW |
|---|---|
| Name | REVELATION BIOSCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 4660 LA JOLLA VILLAGE DRIVE,SUITE 100, SAN DIEGO, California, 92122, United States |
| Telephone | +1 650 - 800-3717 |
| Fax | — |
| — | |
| Website | https://www.revbiosciences.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001810560 |
| Description | Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. Additional info from NASDAQ: |
(70% Positive) REVELATION BIOSCIENCES, INC. (REVBW) Announces Executive Changes
Read moreNew Form DEF 14A - REVELATION BIOSCIENCES, INC. <b>Filed:</b> 2026-05-11 <b>AccNo:</b> 0001193125-26-215804 <b>Size:</b> 2 MB
Read moreNew Form ARS - REVELATION BIOSCIENCES, INC. <b>Filed:</b> 2026-05-11 <b>AccNo:</b> 0001193125-26-215826 <b>Size:</b> 9 MB
Read more(30% Negative) REVELATION BIOSCIENCES, INC. (REVBW) Reports Q2 2026 Financial Results
Read moreRolke James 🔴 sold 10.1K shares of REVELATION BIOSCIENCES, INC. (REVB) at $1.13 Transaction Date: Apr 30, 2026 | Filing ID: 201769
Read moreZygmont Chester Stanley III 🔴 sold 13.3K shares of REVELATION BIOSCIENCES, INC. (REVB) at $1.10 Transaction Date: Apr 30, 2026 | Filing ID: 201764
Read moreNew Form PRE 14A - REVELATION BIOSCIENCES, INC. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001193125-26-196729 <b>Size:</b> 1 MB
Read moreNew Form S-8 - REVELATION BIOSCIENCES, INC. <b>Filed:</b> 2026-04-15 <b>AccNo:</b> 0001193125-26-157022 <b>Size:</b> 721 KB
Read more(99% Neutral) REVELATION BIOSCIENCES, INC. (REVB) Announces Regulatory Update
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06863467 | Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 … | Phase1 | Renal Insufficiency, Chronic | Completed | 2025-01-20 | 2025-07-22 | ClinicalTrials.gov |
| NCT01252095 | Study of the Safety and Tolerability of PG545 in Patients With Advanced Solid T… | Phase1 | Advanced Solid Tumours | Terminated | 2011-01-01 | 2011-10-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| PG545 | Other | Phase PHASE1 | Advanced Solid Tumours | TERMINATED | NCT01252095 |
| PG545 | Other | Phase PHASE1 | Advanced Solid Tumours | TERMINATED | NCT01252095 |
| PG545 | Other | Phase PHASE1 | Advanced Solid Tumours | TERMINATED | NCT01252095 |
| Intravenous placebo | Other | Phase PHASE1 | Renal Insufficiency, Chronic | COMPLETED | NCT06863467 |
| Intravenous Gemini | Other | Phase PHASE1 | Renal Insufficiency, Chronic | COMPLETED | NCT06863467 |
| Intravenous placebo | DRUG | Phase PHASE1 | Renal Insufficiency, Chronic | COMPLETED | NCT06863467 |
| Intravenous Gemini | DRUG | Phase PHASE1 | Renal Insufficiency, Chronic | COMPLETED | NCT06863467 |